GE HealthCare Technologies Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), GE HealthCare Technologies Inc. reported revenue of $20.6B (+4.8% year on year) and net income of $2.2B (+5.1% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY |
|---|---|---|---|
| Total revenues | $20.6B | $19.7B | $19.6B |
| Cost of sales | $12.4B | $11.5B | $11.6B |
| Gross profit | $8.2B | $8.2B | $7.9B |
| Selling, general, and administrative | $4.2B | $4.3B | $4.3B |
| Research and development | $1.3B | $1.3B | $1.2B |
| Total operating expenses | $5.5B | $5.6B | $5.5B |
| Operating income | $2.8B | $2.6B | $2.4B |
| Interest and other financial charges – net | $440.0M | $504.0M | $542.0M |
| Non-operating benefit (income) costs | ($288.0M) | ($406.0M) | ($382.0M) |
| Other (income) expense – net | ($157.0M) | ($55.0M) | ($86.0M) |
| Income from continuing operations before income taxes | $2.8B | $2.6B | $2.4B |
| Benefit (provision) for income taxes | ($614.0M) | ($531.0M) | ($743.0M) |
| Net income from continuing operations | $2.2B | $2.0B | $1.6B |
| Income (loss) from discontinued operations, net of taxes | $0 | $0 | ($4.0M) |
| Net income | $2.2B | $2.0B | $1.6B |
| Net (income) loss attributable to noncontrolling interests | ($70.0M) | ($57.0M) | ($46.0M) |
| Net income attributable to GE HealthCare | $2.1B | $2.0B | $1.6B |
| Deemed preferred stock dividend of redeemable noncontrolling interest | $0 | $0 | ($183.0M) |
| Net income attributable to GE HealthCare common stockholders | $2.1B | $2.0B | $1.4B |
| Basic (in dollars per share) | $4.56 | $4.37 | $3.06 |
| Diluted (in dollars per share) | $4.55 | $4.34 | $3.04 |
| Basic (in shares) | 456.0M | 456.0M | 455.0M |
| Diluted (in shares) | 458.0M | 459.0M | 458.0M |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Total revenues | $5.3B | $5.1B | $5.1B | $5.0B |
| Cost of revenue | $3.1B | $3.2B | $3.2B | $3.0B |
| Gross profit | $2.2B | $2.0B | $2.0B | $2.0B |
| Selling, general, and administrative | $1.1B | $1.1B | $1.0B | $1.0B |
| Research and development | $323.0M | $345.0M | $292.0M | $302.0M |
| Total operating expenses | $1.4B | $1.5B | $1.3B | $1.3B |
| Operating income | $739.0M | $515.0M | $653.0M | $654.0M |
| Interest and other financial charges – net | $114.0M | $96.0M | $111.0M | $113.0M |
| Non-operating benefit (income) costs | ($45.0M) | ($51.0M) | ($75.0M) | ($73.0M) |
| Other (income) expense – net | ($22.0M) | ($36.0M) | ($26.0M) | $1.0M |
| Income before income taxes | $693.0M | $505.0M | $643.0M | $613.0M |
| Benefit (provision) for income taxes | ($119.0M) | ($94.0M) | ($179.0M) | ($113.0M) |
| Net income | $573.0M | $411.0M | $464.0M | $500.0M |
| Net (income) loss attributable to noncontrolling interests | ($13.0M) | ($22.0M) | ($18.0M) | ($14.0M) |
| Net income attributable to GE HealthCare | $561.0M | $389.0M | $446.0M | $486.0M |
| Basic (in dollars per share) | $1.24 | $0.85 | $0.98 | $1.06 |
| Diluted (in dollars per share) | $1.24 | $0.85 | $0.98 | $1.06 |
| Basic (in shares) | 453.0M | 456.0M | 456.0M | 457.0M |
| Diluted (in shares) | 454.0M | 457.0M | 457.0M | 458.0M |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY |
|---|---|---|---|
| Cash, cash equivalents, and restricted cash | $4.5B | $2.9B | $2.5B |
| Receivables – net of allowances of $103 and $103 | $4.0B | $3.6B | $3.6B |
| Inventories | $2.2B | $1.9B | $2.0B |
| Contract and other deferred assets | $1.1B | $974.0M | $1.0B |
| All other current assets | $726.0M | $529.0M | $389.0M |
| Current assets | $12.5B | $9.9B | $9.4B |
| Property, plant, and equipment – net | $3.1B | $2.5B | $2.5B |
| Goodwill | $13.5B | $13.1B | $12.9B |
| Other intangible assets – net | $1.1B | $1.1B | $1.3B |
| Deferred income taxes | $4.5B | $4.5B | $4.5B |
| All other non-current assets | $2.2B | $1.9B | $1.9B |
| Total assets | $36.9B | $33.1B | $32.5B |
| Short-term borrowings | $508.0M | $1.5B | $1.0B |
| Accounts payable | $3.3B | $3.0B | $2.9B |
| Contract liabilities | $2.1B | $1.9B | $1.9B |
| Current compensation and benefits | $1.7B | $1.5B | — |
| All other current liabilities | $1.6B | $1.6B | $3.1B |
| Current liabilities | $9.1B | $9.6B | $9.0B |
| Long-term borrowings | $9.5B | $7.4B | $8.4B |
| Non-current compensation and benefits | $5.5B | $5.6B | $5.8B |
| Deferred income taxes | $193.0M | $56.0M | $68.0M |
| All other non-current liabilities | $2.1B | $1.8B | $1.9B |
| Total liabilities | $26.3B | $24.4B | $25.1B |
| Redeemable noncontrolling interests | $209.0M | $188.0M | $165.0M |
| Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 458,844,209 shares issued as of December 31, 2025; 457,246,971 shares issued as of December 31, 2024 | $5000000.00 | $5000000.00 | $5000000.00 |
| Treasury stock, at cost, 3,107,626 shares as of December 31, 2025 and 291,053 shares as of December 31, 2024 | -225.0M | -25.0M | — |
| Additional paid-in capital | $6.7B | $6.6B | $6.5B |
| Retained earnings | $5.3B | $3.3B | $1.3B |
| Accumulated other comprehensive income (loss) – net | ($1.4B) | ($1.4B) | ($691.0M) |
| Total equity attributable to GE HealthCare | $10.4B | $8.4B | $7.1B |
| Noncontrolling interests | $11.0M | $18.0M | $12.0M |
| Total equity | $10.4B | $8.5B | $7.1B |
| Total liabilities, redeemable noncontrolling interests, and equity | $36.9B | $33.1B | $32.5B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | $2.1B | $2.3B | $4.0B | $3.8B |
| Receivables – net of allowances of $102 and $103 | $3.9B | $3.8B | $3.7B | $3.6B |
| Inventories | $2.5B | $2.4B | $2.3B | $2.3B |
| Contract and other deferred assets | $1.2B | $1.2B | $1.1B | $1.1B |
| All other current assets | $793.0M | $842.0M | $702.0M | $638.0M |
| Current assets | $10.5B | $10.4B | $11.9B | $11.3B |
| Property, plant, and equipment – net | $3.1B | $3.1B | $3.0B | $3.0B |
| Goodwill | $15.1B | $15.1B | $13.4B | $13.4B |
| Other intangible assets – net | $1.9B | $1.9B | $1.2B | $1.2B |
| Deferred income taxes | $4.4B | $4.4B | $4.5B | $4.5B |
| All other non-current assets | $2.3B | $2.3B | $2.2B | $2.1B |
| Total assets | $37.2B | $37.1B | $36.1B | $35.5B |
| Short-term borrowings | $2.0M | $7.0M | $2.0B | $2.0B |
| Accounts payable | $3.2B | $3.4B | $3.0B | $3.0B |
| Contract liabilities | $2.2B | $2.2B | $2.0B | $2.0B |
| Current compensation and benefits | $1.4B | $1.4B | $1.5B | $1.4B |
| All other current liabilities | $1.4B | $1.5B | $1.5B | $1.4B |
| Current liabilities | $8.3B | $8.5B | $10.1B | $9.7B |
| Long-term borrowings | $10.1B | $10.1B | $8.3B | $8.3B |
| Non-current compensation and benefits | $5.2B | $5.3B | $5.3B | $5.4B |
| Deferred income taxes | $315.0M | $256.0M | $171.0M | $173.0M |
| All other non-current liabilities | $2.1B | $2.0B | $2.1B | $2.0B |
| Total liabilities | $26.0B | $26.2B | $25.9B | $25.5B |
| Redeemable noncontrolling interests | $229.0M | $218.0M | $204.0M | $220.0M |
| Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 459,470,464 shares issued as of June 30, 2026; 458,844,209 shares issued as of December 31, 2025 | $5000000.00 | $5000000.00 | $5000000.00 | $5000000.00 |
| Treasury stock, at cost, 7,785,199 shares as of June 30, 2026 and 3,107,626 shares as of December 31, 2025 | -525.0M | -325.0M | -225.0M | -125.0M |
| Additional paid-in capital | $6.8B | $6.7B | $6.7B | $6.6B |
| Retained earnings | $6.2B | $5.7B | $4.7B | $4.3B |
| Accumulated other comprehensive income (loss) – net | ($1.5B) | ($1.4B) | ($1.2B) | ($1.1B) |
| Total equity attributable to GE HealthCare | $11.0B | $10.7B | $10.0B | $9.7B |
| Noncontrolling interests | $14.0M | $12.0M | $23.0M | $21.0M |
| Total equity | $11.0B | $10.7B | $10.0B | $9.7B |
| Total liabilities, redeemable noncontrolling interests, and equity | $37.2B | $37.1B | $36.1B | $35.5B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY |
|---|---|---|---|
| Net income | $2.2B | $2.0B | $1.6B |
| Less: Income (loss) from discontinued operations, net of taxes | $0 | $0 | ($4.0M) |
| Net income from continuing operations | $2.2B | $2.0B | $1.6B |
| Depreciation of property, plant, and equipment | $287.0M | $268.0M | $248.0M |
| Amortization of intangible assets | $291.0M | $312.0M | $362.0M |
| Gain on remeasurement of Nihon Medi-Physics equity method investment | ($97.0M) | — | — |
| Net periodic postretirement benefit plan (income) expense | ($267.0M) | ($357.0M) | ($332.0M) |
| Postretirement plan contributions | ($338.0M) | ($332.0M) | ($357.0M) |
| Share-based compensation | $130.0M | $125.0M | $114.0M |
| Provision for income taxes | $614.0M | $531.0M | $743.0M |
| Cash paid during the year for income taxes | ($429.0M) | ($491.0M) | ($474.0M) |
| Receivables | ($216.0M) | ($178.0M) | ($185.0M) |
| Inventories | ($142.0M) | ($81.0M) | $111.0M |
| Contract and other deferred assets | ($60.0M) | $3.0M | $10.0M |
| Accounts payable | $90.0M | $126.0M | ($13.0M) |
| Contract liabilities | $81.0M | $68.0M | $26.0M |
| Current compensation and benefits | $94.0M | $39.0M | — |
| All other operating activities – net | ($204.0M) | ($74.0M) | $327.0M |
| Cash from (used for) operating activities – continuing operations | $2.0B | $2.0B | $2.1B |
| Additions to property, plant and equipment and internal-use software | ($482.0M) | ($401.0M) | ($387.0M) |
| Dispositions of property, plant, and equipment | $0 | $0 | $1.0M |
| Purchases of businesses, net of cash acquired | ($378.0M) | ($313.0M) | ($147.0M) |
| Purchases of investments | ($118.0M) | ($40.0M) | — |
| All other investing activities – net | ($69.0M) | ($160.0M) | ($25.0M) |
| Cash from (used for) investing activities – continuing operations | ($1.0B) | ($914.0M) | ($558.0M) |
| Net increase (decrease) in borrowings (maturities of 90 days or less) | $1.0M | $0 | ($12.0M) |
| Newly issued debt, net of debt issuance costs (maturities longer than 90 days) | $2.7B | $995.0M | $2.0B |
| Repayments and other reductions (maturities longer than 90 days) | ($1.8B) | ($1.4B) | ($855.0M) |
| Dividends paid to stockholders | ($64.0M) | ($55.0M) | ($41.0M) |
| Repurchase of common stock | ($200.0M) | — | — |
| Redemption of noncontrolling interests | $0 | $0 | ($211.0M) |
| Net transfers (to) from GE | $0 | $0 | ($1.3B) |
| Proceeds from stock issued under employee benefit plans | 37.0M | 33.0M | — |
| Taxes paid related to net share settlement of equity awards | ($42.0M) | ($93.0M) | — |
| All other financing activities – net | ($81.0M) | ($34.0M) | ($48.0M) |
| Cash from (used for) financing activities – continuing operations | $617.0M | ($573.0M) | ($478.0M) |
| Cash from (used for) operating activities – discontinued operations | $0 | ($4.0M) | $0 |
| Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash | $66.0M | ($77.0M) | ($10.0M) |
| Increase (decrease) in cash, cash equivalents, and restricted cash | $1.6B | $387.0M | $1.1B |
| Cash, cash equivalents, and restricted cash at beginning of year | $2.9B | $2.5B | $1.5B |
| Cash, cash equivalents, and restricted cash at end of year | $4.5B | $2.9B | — |
| Cash paid during the year for interest | ($522.0M) | ($550.0M) | ($570.0M) |
| Acquired but unpaid property, plant, and equipment | $164.0M | $143.0M | $140.0M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income | $985.0M | $411.0M | $1.6B | $1.1B |
| Depreciation of property, plant, and equipment | $154.0M | $78.0M | $213.0M | $138.0M |
| Amortization of intangible assets | $159.0M | $75.0M | $219.0M | $146.0M |
| Gain on remeasurement of Nihon Medi-Physics equity method investment | $0 | $0 | ($97.0M) | ($97.0M) |
| Net periodic postretirement benefit plan (income) expense | ($93.0M) | ($47.0M) | ($208.0M) | ($138.0M) |
| Postretirement plan contributions | ($171.0M) | ($97.0M) | ($260.0M) | ($182.0M) |
| Share-based compensation | $80.0M | $35.0M | $94.0M | $56.0M |
| Provision for income taxes | $213.0M | $94.0M | $395.0M | $216.0M |
| Cash paid during the year for income taxes | ($231.0M) | ($92.0M) | ($353.0M) | ($270.0M) |
| Receivables | $62.0M | $141.0M | ($6.0M) | $185.0M |
| Inventories | ($310.0M) | ($171.0M) | ($217.0M) | ($188.0M) |
| Contract and other deferred assets | ($132.0M) | ($46.0M) | ($111.0M) | ($48.0M) |
| Accounts payable | $21.0M | $221.0M | ($119.0M) | ($113.0M) |
| Contract liabilities | $83.0M | $35.0M | $1.0M | ($23.0M) |
| Current compensation and benefits | ($231.0M) | ($250.0M) | ($29.0M) | ($207.0M) |
| All other operating activities – net | ($130.0M) | ($99.0M) | ($136.0M) | ($218.0M) |
| Cash from (used for) operating activities | $458.0M | $290.0M | — | $344.0M |
| Additions to property, plant and equipment and internal-use software | ($278.0M) | ($178.0M) | ($348.0M) | ($238.0M) |
| Purchases of businesses, net of cash acquired | ($2.3B) | ($2.3B) | ($279.0M) | ($279.0M) |
| Purchases of investments | ($19.0M) | ($13.0M) | ($82.0M) | ($28.0M) |
| All other investing activities – net | ($24.0M) | ($13.0M) | ($69.0M) | ($84.0M) |
| Cash from (used for) investing activities | ($2.6B) | ($2.5B) | ($778.0M) | ($630.0M) |
| Net increase (decrease) in borrowings (maturities of 90 days or less) | ($1.0M) | ($1.0M) | — | $1.0M |
| Newly issued debt, net of debt issuance costs (maturities longer than 90 days) | $1.2B | $1.2B | $1.5B | $1.5B |
| Repayments and other reductions (maturities longer than 90 days) | ($1.0B) | ($1.0B) | ($265.0M) | ($261.0M) |
| Dividends paid to stockholders | ($32.0M) | ($16.0M) | ($48.0M) | ($32.0M) |
| Repurchase of common stock | ($300.0M) | ($100.0M) | ($200.0M) | ($100.0M) |
| Proceeds from stock issued under employee benefit plans | 10.0M | 10.0M | 25.0M | 21.0M |
| Taxes paid related to net share settlement of equity awards | ($21.0M) | ($19.0M) | ($41.0M) | ($33.0M) |
| All other financing activities – net | ($12.0M) | ($2.0M) | ($56.0M) | ($15.0M) |
| Cash from (used for) financing activities | ($215.0M) | $21.0M | $910.0M | $1.1B |
| Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash | ($35.0M) | ($37.0M) | $68.0M | $84.0M |
| Increase (decrease) in cash, cash equivalents, and restricted cash | ($2.4B) | ($2.2B) | $1.1B | $873.0M |
| Cash, cash equivalents, and restricted cash at beginning of year | $4.5B | $4.5B | $2.9B | $2.9B |
| Cash, cash equivalents, and restricted cash at end of period | $2.1B | $2.3B | $4.0B | $3.8B |
| Cash paid during the year for interest | ($280.0M) | ($87.0M) | ($327.0M) | ($260.0M) |
| Acquired but unpaid property, plant, and equipment | $102.0M | $86.0M | $111.0M | $90.0M |
GE HealthCare Technologies Inc. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.